🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccine schedules, an unexpected name has surfaced unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines in the global health crisis and has zeroed in on possible fatalities following Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Agency leaders were set to reveal sweeping changes to the pediatric immunization program in December, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of step with a large portion of the global community with little proof for benefit. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to run the office this year.

A Shift at the Agency

This interim role may indicate a closer partnership between the drug and biologics branches as Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for halting specific childhood vaccine recommendations in the US so as to align more similar to the Danish model, a society with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Questions Over Expertise

Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been standard for former heads of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a major agency. She is not an expert in drug approvals.”

Past directors of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that prior appointees who led the center have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and every single one have to be managed,” she said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the position, which supervises more than 5,000 personnel. “It’s a huge leadership role, if you do it right,” she concluded.

Official Statement and Controversial Policies

When asked about questions about Høeg’s qualifications and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries stem from inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her role,” the spokesperson stated, citing the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's recently launched expedited review system, a contentious one-day therapy clearance system that apparently worried her preceding directors. “By what process are these therapies being picked for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, some experts have noted. She released a analysis using unverified crowd-sourced reports to assess the rate of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current federal leadership featured altering guidelines for new vaccines and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing teenage boys from receiving Covid vaccinations.

“She is an all-around ideologue who starts off with her preconceived notions and tailors the evidence to fit the data in a highly deceptive, dishonest manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|